Stanozolol

CHEMBL2079587 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
328.5 g/mol
LogP
4.5
Phase
4

Stanozolol is a synthetic 17-alkylated anabolic-androgenic steroid (AAS) derived from dihydrotestosterone, used medically to treat hereditary angioedema and vascular manifestations of Behcet's disease by increasing synthesis of C1-esterase inhibitor. Like other androgens, it binds to androgen receptors to promote nitrogen retention, muscle protein synthesis, and erythropoiesis, while also stimulating production of C1-inhibitor. It is a Schedule III controlled substance due to high abuse potential in sports doping.

분자량

328.5000 g/mol

LogP

4.50

TPSA

48.90 Ų

리핀스키 5의 법칙

통과

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O

InChI

InChI=1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1

Molecular Formula

C21H32N2O

HBD / HBA

2 / 2

회전 가능 결합

0

무거운 원자

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Stanozolol is a synthetic 17-alkylated anabolic-androgenic steroid (AAS) derived from dihydrotestosterone, used medically to treat hereditary angioedema and vascular manifestations of Behcet's disease by increasing synthesis of C1-esterase inhibitor. Like other androgens, it binds to androgen receptors to promote nitrogen retention, muscle protein synthesis, and erythropoiesis, while also stimulating production of C1-inhibitor. It is a Schedule III controlled substance due to high abuse potential in sports doping.

Yes, Stanozolol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2079587. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25249. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.